U.S. Consumer Product Safety Commission

LOG OF MEETING

SUBJECT: Chronic Hazard Advisory Panel (CHAP) on Phthalates and Phthalate Substitutes

DATE: December 2-3, 2010

TIME: 8:30 a.m. to 5:00 p.m. on December 2, and 8:30 a.m. to 11:30 a.m. December 3

PLACE: CPSC Headquarters

ENTRY SOURCE: Michael Babich, HSHS

COMMISSION REPRESENTATIVE: Michael Babich

CHAP Members: Philip Mirkes (Chair), Bernard Schwetz (Vice-Chair), Chris Gennings, Russ Hauser, Holger Koch, Andreas Kortenkamp, Paul Lioy.

NON FEDERAL REPRESENTATIVES: See attendee list.

SUMMARY:

This was the third meeting of the 2010 Chronic Hazard Advisory Panel (CHAP) on Phthalates and Phthalate Substitutes. Following introductions, Dr. Babich, CPSC, presented an update on CPSC staff activities. The CPSC staff is preparing toxicity reviews for 29 phthalates not covered by the Consumer Product Safety Improvement Act of 2008 (CPSIA). These 29 phthalates were divided into four prioritized tiers. A report on 17 Tier 3 and Tier 4 phthalates prepared by the CPSC staff was presented to the CHAP. A contractor is preparing reports on 10 Tier 1 and Tier 2 phthalates. The CPSC staff is also preparing reports on two additional Tier 2 and 3 phthalates and one additional phthalate substitute.

The CHAP then heard presentations from three invited experts. Dr. Richard Stahlhut, University of Rochester, School of Medicine and Dentistry, spoke about the use of biomonitoring data to estimate human exposure to phthalates and other chemicals. In particular, he discussed the possible effects of fasting times on urinary metabolite levels measured in the National Health and Nutrition Examination Survey (NHANES). Dr. Thomas Burke, Johns Hopkins University, Bloomberg School of Public Health, spoke about the 2008 National Academy of Sciences report on risk assessment, as it relates to the CHAP's risk assessment on phthalates. Matthew Lorber, U.S. EPA, National Center for Environmental Assessment, spoke about the estimation of human exposure from biomonitoring data and from phthalate levels in environmental media and products. The presentations were followed by a general discussion with the CHAP members.

Following the lunch break. Dr. Gennings described a possible approach for calculating hazard indices for cumulative exposures from biomonitoring data. Drs. Mirkes and Schwetz discussed the CHAP's overall approach to conducting the risk assessment. These topics were previously discussed in the November 15 teleconference. In addition,

there was discussion about exposure assessment, whether to include non-phthalate antiandrogens in the risk assessment, and the scope of the risk assessment.

On the second day, Dr. Gennings presented some additional analyses relating to the effect of fasting on biomonitoring data. The CHAP then discussed their approach for conducting the risk assessment. It was agreed that Drs. Schwetz, Mirkes, and Kortenkamp would review the animal toxicity data, with assistance from the CPSC staff. Dr. Hauser would review the epidemiology data. Dr. Lioy would perform the scenario-based exposure assessment, that is, he would estimate the exposure from children's products. Dr. Lioy will be assisted by Dr. Koch and the CPSC staff. Drs. Gennings and Koch will estimate total exposure and calculate hazard indices from biomonitoring data. To support the work of Drs. Gennings and Koch, the CPSC staff will try to obtain additional biomonitoring data on pregnant women and infants from the authors of published studies. The method described by Dr. Gennings requires data on individuals, rather than summary data.

The CHAP decided to cancel the planned January meeting so that the members could begin drafting their sections of the report. The CHAP will meet again on March 30-31, 2011 at CPSC headquarters.

Attachments:

- Agenda
- List of meeting attendees

Supplemental Information is available at:
http://www.cpsc.gov/about/cpsia/chap0710.html)

- Video recording of the meeting
- Speakers' slides